Around 80% of patients with atrial fibrillation are successfully treated at Moncloa University Hospital

Around 80% of patients with atrial fibrillation are successfully treated at Moncloa University Hospital, according to the statement made by the medical director of the hospital and director of the Espriu Foundation, Carlos Zarco, on the occasion of Heart Week, which falls this year from 25 September to 1 October, with the aim of raising awareness in society about the cardiovascular disease and of preventing its occurrence.

Atrial fibrillation is the most common form of arrhythmia diagnosed in people over 50 years old and it can increase a patient’s risk of having a stroke by up to five times. The Arrhythmias Unit at the Moncloa University Hospital, which belongs to the HLA-ASISA group and in turn to the Espriu Foundation, is a leader in Spain in terms of treating atrial fibrillation with cold; using a pioneering technique that allows the pulmonary veins to be electrically disconnected from the left atrium, which are the main causes of the disease, as explained by Dr Zarco.

The Hospital’s Arrhythmias Unit, which is led by Doctor Paylos González, treats the three stages of atrial fibrillation. The first is known as the paroxysmal phase, where the episodes do not last more than 24 hours and disappear spontaneously. In these cases a cure rate of more than 90% has been achieved.

The second is short-duration persistent atrial fibrillation, with episodes lasting 7 to 10 days and which respond to medication. In these types of patients, the cure rate with cold is between 60 and 80%, according to the data available. Lastly is long-duration persistent atrial fibrillation, where the patient has been suffering for a longer time and has already undergone atrial remodelling. The cure rate in these cases is 60% after the first medical intervention.

With this data, the director of the Espriu Foundation stressed that the professionals from this unit adapt to the characteristics and constraints of each patient, always aiming to provide personalised heart disease treatment in order to achieve more cases of success. He also revealed that the main objective for the upcoming years is to improve the percentage of positive results, especially in the more advanced phases of this type of disease.